Clozapine and risperidone influence on metabolic parameters and liver function in patients with schizophrenia

Radonjić, Katarina

doi:10.5937/mckg47-2795

Akcije

dodaj u Moj izbor [0]

kako citirati ovaj članak
prikaži na oba jezika
podeli ovaj članak

Direktan link

Metrika

citati u SCIndeksu: 0
citati u CrossRef-u:0
citati u Google Scholaru:[]
posete u poslednjih 30 dana:1
preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 1 od 1

Medicinski časopis

2013, vol. 47, br. 1, str. 24-29

Uticaj klozapina i risperidona na metaboličke parametre i funkciju jetre kod pacijenata sa šizofrenijom

Radonjić Katarina

Univerzitet u Kragujevcu, Fakultet medicinskih nauka, Srbija

e-adresa: katarina7_mih@yahoo.com

Ključne reči: klozapin; risperidon; šizofrenija; hemijska analiza krvi; toksičnost lekova

Sažetak

Cilj. Poznato je da atipični antipsihotici dovode do metaboličkih poremećaja i oštećenja jetre. Ciljevi studije bili su da se ispita da li klozapin i risperidon utiču na povećanje nivoa glukoze, holesterola, transaminaza i bilirubina u serumu, i da se utvrdi da li postoji razlika između ovih antipsihotika u uticaju na pomenute biohemijske parametre. Metode. Istraživanje je sprovedeno kao studija preseka bolnički lečenih pacijenata na Psihijatrijskoj klinici KC 'Kragujevac' tokom 2009. godine. Uključeni su pacijenti sa šizofrenijom koji su bili na terapiji klozapinom ili risperidonom. Za analizu su korišćeni rezultati laboratorijskih analiza koje su pacijentima urađene tokom bolničkog tretmana. Za statističku obradu podataka koristili su se z-test, Studentov t-test i deskriptivna statistika. Rezultati: U istraživanje je uključen 91 pacijent. Zastupljena su pacijenti oba pola, od 21 do 73 godine, koji su podeljeni u dve grupe na osnovu terapije koju su dobijali: klozapin (n = 44) i risperidon (n = 47). Učestalost povišene glukoze kod pacijenata na klozapinu bila je 41,46% naspram 27,66% kod pacijenata na risperidonu. Učestalost povišenog holesterola kod pacijenata na klozapinu bila je 23,08% naspram 35,29% kod pacijenata na risperidonu. Sedam pacijenata od ukupno 42 lečenih klozapinom (16,67%) imalo je znatno povećanje AST u poređenju sa tri od 46 pacijenata lečenih risperidonom (6,52%). Ipak, nije nađena statistički značajna razlika između njih. Zaključak. Rezultati su pokazali da klozapin i risperidon utiču na povećanje vrednosti metaboličkih parametara i parametara funkcije jetre kod pacijenata sa šizofrenijom, ali među njima nije utvrđena statistički značajna razlika. Te pacijente treba redovno biohemijski pratiti da bi se blagovremeno otkrili mogući neželjeni efekti.

Abstract

Objective. It is well known that atypical antipsychotics cause metabolic disturbances and liver dysfunction. The aims of the study were to explore whether clozapine and risperidone increase glucose, cholesterol, transaminases and bilirubin levels in serum, and to determine whether there is a difference in influence on mentioned biochemical parameters between these antipsychotics. Methods. A cross-sectional study of the patients hospitalized in 2009 in Psychiatric Clinic, Clinical Center 'Kragujevac' was done. Patients with schizophrenia treated with clozapine or risperidone were included. The results of laboratory parameters which were performed for patients during their hospital treatment were used for analysis. Statistical analysis was performed by using z-test, Student's t-test and descriptive statistics. Results. The study included 91 patients, both genders, aged 21-73, which were divided into two groups according to the treatment: clozapine (n=44) and risperidone (n=47). The frequency of elevated glucose level in clozapine-treated group was 41.46% vs. 27.66% in risperidone-treated group. The frequency of elevated cholesterol level in clozapinetreated group was 23.08% vs. 35.29% in risperidone-treated group. Seven of 42 patients in clozapine-treated group (16.67%) had a significant increase in AST, in comparison with 3 of 46 patients in risperidone-treated group (6.52%). However, there was no statistically significant difference between the groups. Conclusion. The results showed that clozapine and risperidone had an influence on increased values of metabolic parameters and parameters of liver function in patients with schizophrenia, but there was no statistically significant difference between these drugs. These patients should be regularly biochemically monitored for early detection of possible side effects.

	Reference
	*** (2009) SPSS for windows: Rel. 18.O.0. Chicago: SPSS Inc
2	American Diabetes Association (2004) Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, 27(2): 596-601
	Casey, D.E., Haupt, D.W., Newcomer, J.W., Henderson, D.C., Sernyak, M.J., Davidson, M., Lindenmayer, J., Manoukian, S.V., Banerji, M.A., Lebovitz, H.E., Hennekens, C.H. (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. Journal of clinical psychiatry, 65 Suppl 7: 4-18; quiz 19-20
	Davis, J.M., Chen, N. (2005) Old versus new: weighing the evidence between the first- and second-generation antipsychotics. European psychiatry, 20(1): 7-14
	Dumortier, G., Cabaret, W., Stamatiadis, L., Saba, G., Benadhira, R., Rocamora, J., Aubriot-Delmas, B., Glikman, J., Januel, D. (2002) Hepatic tolerance of atypical antipsychotic drugs. L'Encéphale, 28(6 Pt 1): 542-51
17	Faul, F., Erdfelder, E., Lang, A., Buchner, A. (2007) GPower 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior research methods*, 39(2): 175-91
1	Fleischhacker, W.W., Cetkovich-Bakmas, M., De, H.M., Hennekens, C.H., Lambert, M., Leucht, S., Maj, M., McIntyre, R.S., Naber, D., Newcomer, J.W., Olfson, M., Osby, U., Sartorius, N., Lieberman, J.A. (2008) Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Journal of clinical psychiatry, 69(4): 514-9
	Gaertner, I., Altendorf, K., Batra, A., Gaertner, H.J. (2001) Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. Journal of clinical psychopharmacology, 21(2): 215-22
3	Harris, E.C., Barraclough, B. (1998) Excess mortality of mental disorder. British journal of psychiatry, 173: 11-53
	Hummer, M., Kurz, M., Kurtzhaler, I., i dr. (1997) Hepatotoxicity of clozapine. J Clin Pharmacol, 17: 314-317
	Koro, C.E., Fedder, D.O., L'Italien, G.J., Weiss, S.S., Magder, L.S., Kreyenbuhl, J., Revicki, D.A., Buchanan, R.W. (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ (Clinical research ed.), 325(7358): 243
	Leitão-Azevedo, C.L., Guimarães, L.R., de Abreu, M.G.B., Gama, C.S., Lobato, M.I., Belmonte-de-Abreu, P.S. (2006) Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Revista brasileira de psiquiatria, 28(4): 301-4
	Lewis, J.H. (2000) Drug-induced liver disease. Med Clin North Am, 84: 1275-1311
	Lindenmayer, J., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J.P., Cooper, T.B., Chakos, M., Lieberman, J.A. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American journal of psychiatry, 160(2): 290-6
	Melkersson, K., Dahl, M. (2004) Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs, 64(7): 701-23
	Meyer, J.M. (2001) Novel antipsychotics and severe hyperlipidemia. Journal of clinical psychopharmacology, 21(4): 369-74
	Meyer, J.M., Koro, C.E. (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia research, 70(1): 1-17
	Mouradian-Stamatiadis, L., Dumortier, G., Januel, D., Delmas, B.A., Cabaret, W. (2002) Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients. Progress in neuro-psychopharmacology & biological psychiatry, 26(7-8): 1409-11
1	Newcomer, J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19(1S): 1-93
1	Selim, K., Kaplowitz, N. (1999) Hepatotoxicity of psychotropic drugs. Hepatology (Baltimore, Md.), 29(5): 1347-51
	Sernyak, M.J., Leslie, D.L., Alarcon, R.D., Losonczy, M.F., Rosenheck, R. (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American journal of psychiatry, 159(4): 561-6
	Smith, R.C., Lindenmayer, J., Bark, N., Warner-Cohen, J., Vaidhyanathaswamy, S., Khandat, A. (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 8(2): 183-94
1	Tarricone, I., Casoria, M., Ferrari, B., i dr. (2006) Metabolic risk factor profile associated with use of second generation antipsychotics: A cross sectional study in a community mental health centre. BMC Psychiatry, 6:1-8

O članku

jezik rada: srpski
vrsta rada: stručni članak
DOI: 10.5937/mckg47-2795
objavljen u SCIndeksu: 05.03.2013.

Povezani članci

Nema povezanih članaka